BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 28752601)

  • 1. Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era.
    Murphy N; O'Mahony B; Flanagan P; Noone D; White B; Bergin C; Norris S; Thornton L;
    Haemophilia; 2017 Sep; 23(5):712-720. PubMed ID: 28752601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
    J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment.
    Maor Y; Schapiro JM; Bashari D; Martinowitz U
    Ann Hepatol; 2014; 13(6):753-61. PubMed ID: 25332261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
    Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
    AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.
    Pineda JA; Núñez-Torres R; Téllez F; Mancebo M; García F; Merchante N; Pérez-Pérez M; Neukam K; Macías J; Real LM;
    J Infect; 2015 Nov; 71(5):571-7. PubMed ID: 26212868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
    PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
    Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
    Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of hepatitis C virus infection in Korea.
    Suh DJ; Jeong SH
    Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach.
    Cachay ER; Mena A; Morano L; Benitez L; Maida I; Mendoza C; Hill L; Torriani F; Soriano V; Mathews WC;
    J Int Assoc Provid AIDS Care; 2021; 20():23259582211024771. PubMed ID: 34132142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
    Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
    Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
    Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
    Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
    Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
    Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment.
    Posthouwer D; Plug I; van der Bom JG; Fischer K; Rosendaal FR; Mauser-Bunschoten EP
    Haemophilia; 2005 May; 11(3):270-5. PubMed ID: 15876273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s.
    Garvey P; Murphy N; Flanagan P; Brennan A; Courtney G; Crosbie O; Crowe J; Hegarty J; Lee J; McIver M; McNulty C; Murray F; Nolan N; O'Farrelly C; Stewart S; Tait M; Norris S; Thornton L
    J Hepatol; 2017 Dec; 67(6):1140-1147. PubMed ID: 28843656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.
    Song AT; Sobesky R; Vinaixa C; Dumortier J; Radenne S; Durand F; Calmus Y; Rousseau G; Latournerie M; Feray C; Delvart V; Roche B; Haim-Boukobza S; Roque-Afonso AM; Castaing D; Abdala E; D'Albuquerque LA; Duclos-Vallée JC; Berenguer M; Samuel D
    World J Gastroenterol; 2016 May; 22(18):4547-58. PubMed ID: 27182164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
    d'Arminio Monforte A; Cozzi-Lepri A; Ceccherini-Silberstein F; De Luca A; Lo Caputo S; Castagna A; Mussini C; Cingolani A; Tavelli A; Shanyinde M; Gori A; Girardi E; Andreoni M; Antinori A; Puoti M;
    PLoS One; 2017; 12(5):e0177402. PubMed ID: 28520749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral pathogens.
    Ragni MV; Sherman KE; Jordan JA
    Haemophilia; 2010 Jul; 16 Suppl 5():40-6. PubMed ID: 20590855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.